Current Report Filing (8-k)
April 15 2020 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
Date of
report (Date of earliest event reported)
|
April
14, 2020
|
AIFARM, LTD.
(Exact
Name of Registrant as Specified in Charter)
Nevada
(State
or Other Jurisdiction of Incorporation)
|
001-37630
|
47-3444723
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
Unit 503, 5/F, Silvercord Tower 2,
30 Canton Road, TST,
Kowloon, Hong Kong
|
N/A
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(852) 91235575
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
AIFarm,
Ltd. (the “Company”) is filing this Current Report on
Form 8-K in compliance with and in reliance upon the SEC Order
issued pursuant to Section 36 of the Securities Exchange Act of
1934, as amended, granting Exemptions from Specified Provisions of
the Exchange Act and Certain Rules thereunder (SEC Release No.
34-88465 on March 25, 2020) (the “Relief Order”). Set
forth below are the reasons for the delays in the completion of the
Annual Report on Form 10-K for the fiscal year ended December 31,
2019 (the “Annual Report”), estimated filing dates of
the Annual Report, and new CODID-19 related risk
disclosure.
The
Company previously announced that it expected to file its Annual
Report within the extension period afforded by SEC Rule 12b-25. As
a result of the increasing challenges associated with the COVID-19
outbreak, the Company does not expect to file the Annual Report
until after such extension period. The Company filed this Current
Report on Form 8-K today to outline its reliance on the relief from
the original filing deadline provided by the SEC, and the Annual
Report filing extension permitted thereunder. The extension of time
is necessary due to unanticipated delays being experienced by the
Company and its auditors in completing the field work associated
with the audit of the Company’s financial statements and the
Company’s completing its Annual Report. Particularly, given
that the auditor personnel has been and continues to work remotely,
and therefore has been unable to visit various field locations to
perform the work necessary to complete the audit. Considering the
lack of time for the compilation, attesting and review of the
information required to be presented and the importance of markets
and investors receiving materially accurate information in the
Annual Report, as of the date of this filing, the Company expects
to file the Annual Report no later than May 14, 2020.
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
AIFARM,
LTD
|
|
|
|
|
|
|
|
|
|
Date:
April 14, 2020
|
By:
|
/s/ Yuen May Cheung
|
|
|
|
Yuen
May Cheung
|
|
|
|
Chief
Executive Officer
|
AIFarm (CE) (USOTC:AIFM)
Historical Stock Chart
From Dec 2024 to Jan 2025
AIFarm (CE) (USOTC:AIFM)
Historical Stock Chart
From Jan 2024 to Jan 2025
